Atantares key facts
as of Oct 2026- Developer of precision medicines and smart diagnostic devices designed to transform disease management across hematology, cardiology, neurology and cancer.
- Atantares is valued at approximately $14.5M as of Oct 2026 (last reported valuation).
- It has raised $28.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include US National Science Foundation, Qiming Venture Partners, Aramco Ventures, Frees Fund, Leader Venture Capital — 17 tracked in total.
- Status: Privately Held (backing).
Atantares's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Atantares: the Monday email on marks, rounds and moves
Atantares funding rounds
No funding rounds for Atantares are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Atantares
17+Atantares valuation
Atantares's last reported valuation was $14.5 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Atantares investors
17 investors are on record for Atantares, including US National Science Foundation, Qiming Venture Partners, Aramco Ventures and Frees Fund.
About Atantares
Developer of precision medicines and smart diagnostic devices designed to transform disease management across hematology, cardiology, neurology and cancer. The company offers a coagulation device that helps in monitoring specific drugs or blood products, using coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform and chimeric antigen receptor, thereby enabling the next generation of precision medicine by fusing biochips and AI technologies.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Employees
- 60
- Website
- atantares.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.